Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | LDHB | P07195 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100915 | 0.91 | CSF1R (0.66) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL29415597 | 0.90 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL30738060 | 0.90 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL20100984 | 0.90 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL17324860 | 0.90 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL20101067 | 0.90 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL18867902 | 0.90 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL18023958 | 0.87 | CSF1R (0.69) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL20100911 | 0.85 | CSF1R (0.74) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL18023934 | 0.85 | CSF1R (0.88) | CSF1RRETPDGFRBKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019157337-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PULMOKINE, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | PULMOKINE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018081567-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180117039-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885RET 236/4885PDGFRB 3/4885 |
| US-20180117039-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885RET 236/4885PDGFRB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.